A (-5, -7) ProPSA Based Artificial Neural Network to Detect Prostate Cancer

European Urology

Volumn 50, Issue 5, 2006, Pages 1014-1020

  Stephan, Carsten ^a   Meyer, Hellmuth Alexander ^a   Kwiatkowski, Maciej ^b   Recker, Franz ^b   Cammann, Henning ^a   Loening, Stefan A ^a   Jung, Klaus ^a   Lein, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

ANN; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER CYTODIAGNOSIS; CANCER PATIENT; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; ROC CURVE;

HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN PRECURSORS; ROC CURVE;

EID: 33749451032     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.04.011     Document Type: Article

References (27)

1. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162 (1999) 293-306
2. Stephan C., Jung K., Diamandis E.P., Rittenhouse H.G., Lein M., and Loening S.A. Prostate specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 59 (2002) 2-8
3. Mikolajczyk S.D., Marks L.S., Partin A.W., and Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 59 (2002) 797-802
4. Mikolajczyk S.D., Grauer L.S., Millar L.S., Hill T.M., Kumar A., Rittenhouse H.G., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50 (1997) 710-714
5. Mikolajczyk S.D., Marker K.M., Millar L.S., Kumar A., Saedi M.S., Payne J.K., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 (2001) 6958-6963
6. Peter J., Unverzagt C., Krogh T.N., Vorm O., and Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61 (2001) 957-962
7. Hoesel W., Peter J., and Hübel-Parajsz C. Development and evaluation of an ELISA for the measurement of proPSA forms in sera. Anticancer Res 22 (2002) 529
8. Bangma C.H., Wildhagen M.F., Yurdakul G., Schroder F.H., and Blijenberg B.G. The value of (-7, -5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93 (2004) 720-724
9. Lein M., Semjonow A., Graefen M., Kwiatkowski M., Abramjuk C., Stephan C., et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 174 (2005) 2150-2153
10. Peyromaure M., Fulla Y., Debre B., and Dinh-Xuan A.T. Pro PSA: a "pro cancer" form of PSA?. Med Hypotheses 64 (2005) 92-95
11. Carlson G.D., Calvanese C.B., and Partin A.W. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 52 (1998) 455-461
12. Virtanen A., Gomari M., Kranse R., and Stenman U.H. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45 (1999) 987-994
13. Babaian R.J., Fritsche H., Ayala A., Bhadkamkar V., Johnston D.A., Naccarato W., et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 56 (2000) 1000-1006
14. Djavan B., Remzi M., Zlotta A., Seitz C., Snow P., and Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20 (2002) 921-929
15. Finne P., Finne R., Auvinen A., Juusela H., Aro J., Maattanen L., et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 56 (2000) 418-422
16. Stephan C., Jung K., Cammann H., Vogel B., Brux B., Kristiansen G., et al. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int J Cancer 99 (2002) 466-473
17. Meyer A., Jung K., Lein M., Rudolph B., Schnorr D., and Loening S.A. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer 74 (1997) 630-636
18. Stephan C., Jung K., Soosaipillai A., Yousef G.M., Cammann H., Meyer H., et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 96 (2005) 521-527
19. Stephan C., Cammann H., Semjonow A., Diamandis E.P., Wymenga L.F.A., Lein M., et al. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48 (2002) 1279-1287
20. Kairisto V., and Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 55 (1995) 43-60
21. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 6 (1979) 65-70
22. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
23. Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Amirkhan A., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 (2003) 2181-2185
24. Khan M.A., Sokoll L.J., Chan D.W., Mangold L.A., Mohr P., Mikolajczyk S.D., et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 64 (2004) 1160-1164
25. Catalona W.J., Bartsch G., Rittenhouse H.G., Evans C.L., Linton H.J., Horninger W., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 (2004) 2239-2244
26. Mikolajczyk S.D., Catalona W.J., Evans C.L., Linton H.J., Millar L.S., Marker K.M., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 (2004) 1017-1025
27. Sokoll L.J., Chan D.W., Mikolajczyk S.D., Rittenhouse H.G., Evans C.L., Linton H.J., et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: preliminary analysis. Urology 61 (2003) 274-276